At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 157 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Daily-dose, Proof-of-concept Study of a Vitamin D Compound in Postmenopausal Women With Osteopenia
In Brief
A Phase 2 clinical trial evaluating Placebo and DP001 for Osteoporosis. Completed, enrolled 157 participants across 9 sites.
Detailed Summary
This study will evaluate the effect of a 1-year administration of the vitamin D analog 2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3 (DP001) on bone mineral density (BMD), safety, and tolerability.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedJul 2008
Primary CompletionDec 2008
Study CompletionJan 2009
TodayJul 2026
First PostedJul 15, 2008
Enrollment StartMar 1, 2007
Primary CompletionDec 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.0 years ago
Interventions
Placebodrug
oral, once daily
DP001drug
oral, once daily